Carna Biosciences, Inc. Stock: price and insider trades · Japan
カルナバイオサイエンス株式会社
1 insider bought €4.4M of shares over the last 90 days, the latest by Gomi Daisuke, filed 20 Oct 2026.
Carna Biosciences, Inc.: what insiders have been doing
Carna Biosciences, Inc. belongs to the Health Care sector. Filings by its managers are published through EDINET (Japan FSA). Between 6 November 2025 and 6 November 2026, 3 insiders published 29 filings.
Purchases and sales both appear in the filings: 7 purchases (1 insider, €4.0M) and 9 sales (2 insiders, €888k). The amount is not disclosed for 9 filings. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Biggest ticket of the year: €3.9M, bought by Gomi Daisuke and made public on 20 October 2026 (9.4% of market cap). Among those who bought: 1 major shareholder.
Compared with its exchange (3,223 companies, median 3 filings), a count of 29 filings is above the norm. Over the whole record (from 2022), the tally stands at 7 purchases and 14 sales.
The clock since the last published purchase (20 October 2026) now reads 19 days. Filings reach the EDINET (Japan FSA) feed a median of 7 days after the trade. That lag is the time during which only the insider knows about the trade. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning.
Other companies in the same sector with recent insider buying flagged by our signals: Dynavox Group AB and Vetoquinol SA. Every figure here comes from the filings published by EDINET (Japan FSA) and describes the past, not future prices; it is not investment advice.
Who traded when
BuySaleSince the insiders bought
- +3.3%Entry JP¥336 · Close 04 Nov 2026 JP¥347
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
- ShareXTKSEDINET:S100ZCIW
- 10,000 sharesShareXTKSEDINET:S100Z93Q:T12Canonical exit: 11 Jan 2027 (T+90)
- ShareXTKSEDINET:S100Z93Q
- 1,000 sharesShareXTKSEDINET:S100Z93Q:T10
- 16,000 sharesShareXTKSEDINET:S100Z93Q:T11Canonical exit: 7 Jan 2027 (T+90)
- 1,709,500 shares@ JP¥409.509.43% mcap98.2% of flowShareXOFFEDINET:S100Z93Q:T13Canonical exit: 12 Jan 2027 (T+90)
- 157,114 shares@ JP¥247.230.53% mcap25.1% of flowShareXOFFEDINET:S100Z8T6:T9
- 157,114 shares@ JP¥247.530.52% mcap25.0% of flowShareXOFFEDINET:S100Z8T6:T13
- ShareXTKSEDINET:S100Z8T6
- ShareXTKSEDINET:S100Z84M
- 2,000 sharesShareXTKSEDINET:S100Z84M:T3
- 5,000 sharesShareXTKSEDINET:S100Z84M:T8Canonical exit: 4 Jan 2027 (T+90)
- 140,000 sharesShareXTKSEDINET:S100Z84M:T9Canonical exit: 5 Jan 2027 (T+90)
- 5,000 shares@ JP¥450.00020.030% mcap17.2% of flowShareXOFFEDINET:S100Z84M:T6
- 30,000 shares@ JP¥360.99990.15% mcap82.8% of flowShareXOFFEDINET:S100Z84M:T7Canonical exit: 4 Jan 2027 (T+90)
- 13,900 sharesShareXTKSEDINET:S100Z84M:T2Canonical exit: 16 Nov 2026 (T+90)
- 3,900 sharesShareXTKSEDINET:S100Z84M:T1
- 5,000 sharesShareXTKSEDINET:S100Z84M:T5
- 4.0% of flowShareXTKSEDINET:S100Z77V
- 157,114 shares@ JP¥263.430.56% mcap53.4% of flowShareXOFFEDINET:S100Z77V:T6
- 157,114 shares@ JP¥238.530.49% mcap46.6% of flowShareXOFFEDINET:S100Z77V:T3
- 6.1% of flowShareXTKSEDINET:S100YSVX
- 9.5% of flowShareXTKSEDINET:S100Y83T
- 9,789,881 shares100.0% of flowShareXTKSEDINET:S100Y2RZ
- 26.5% of flowShareXTKSEDINET:S100Y1G1
25 of 57 declarations
About Carna Biosciences, Inc.
Karuna Biosciences is a company focused on the healthcare and pharmaceutical sector. It is listed on the XTKS market.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
